Physiologic postoperative presepsin kinetics following primary cementless total hip arthroplasty: A prospective observational study.

Hip surgery Periprosthetic joint infection Postoperative care Presepsin Total hip arthroplasty Total hip replacement

Journal

World journal of orthopedics
ISSN: 2218-5836
Titre abrégé: World J Orthop
Pays: United States
ID NLM: 101576349

Informations de publication

Date de publication:
18 Jul 2023
Historique:
received: 23 12 2022
revised: 09 03 2023
accepted: 12 06 2023
medline: 24 7 2023
pubmed: 24 7 2023
entrez: 24 7 2023
Statut: epublish

Résumé

Presepsin is an emerging biomarker in the diagnosis of sepsis. In the field of orthopaedics, it could be useful in diagnosing and managing periprosthetic joint infections. To define the normal postoperative presepsin plasmatic curve, in patients undergoing primary cementless total hip arthroplasty (THA). Patients undergoing primary cementless THA at our Institute were recruited. Inclusion criteria were: Primary osteoarthritis of the hip; urinary catheter time of permanence < 24 h; peripheral venous cannulation time of permanence < 24 h; no postoperative homologous blood transfusion administration and hospital stay ≤ 8 d. Exclusion criteria were: The presence of other articular prosthetic replacement or bone fixation devices; chronic inflammatory diseases; chronic kidney diseases; history of recurrent infections or malignant neoplasms; previous surgery in the preceding 12 mo; diabetes mellitus; immunosuppressive drug or corticosteroid assumption. All the patients received the same antibiotic prophylaxis. All the THA were performed by the same surgical and anaesthesia team; total operative time was defined as the time taken from skin incision to completion of skin closure. At enrollment, anthropometric data, smocking status, osteoarthritis stage according to Kellgren and Lawrence, Harris Hip Score, drugs assumption and comorbidities were recorded. All the patients underwent serial blood tests, including complete blood count, presepsin (PS) and C-reactive protein 24 h before arthroplasty and at 24, 48, 72 and 96 h postoperatively and at 3, 6 and 12-mo follow-up. A total of 96 patients (51 female; 45 male; mean age = 65.74 ± 5.58) were recruited. The mean PS values were: 137.54 pg/mL at baseline, 192.08 pg/mL at 24 h post-op; 254.85 pg/mL at 48 h post-op; 259 pg/mL at 72 h post-op; 248.6 pg/mL at 96-h post-op; 140.52 pg/mL at 3-mo follow-up; 135.55 pg/mL at 6-mo follow-up and 130.11 pg/mL at 12-mo follow-up. In two patients (2.08%) a soft-tissue infection was observed; in these patients, higher levels (> 350 pg/mL) were recorded at 3-mo follow-up. The dosage of plasmatic PS concentration is highly recommended in patients undergoing THA before surgery to exclude the presence of an unknown infection. The PS plasmatic concentration should be also assessed at 72 h post-operatively, evaluate the maximum postoperative PS value, and at 96 h post-operatively when a decrease of presepsin should be found. The lack of a presepsin decrease at 96 h post-operatively could be a predictive factor of infection.

Sections du résumé

BACKGROUND BACKGROUND
Presepsin is an emerging biomarker in the diagnosis of sepsis. In the field of orthopaedics, it could be useful in diagnosing and managing periprosthetic joint infections.
AIM OBJECTIVE
To define the normal postoperative presepsin plasmatic curve, in patients undergoing primary cementless total hip arthroplasty (THA).
METHODS METHODS
Patients undergoing primary cementless THA at our Institute were recruited. Inclusion criteria were: Primary osteoarthritis of the hip; urinary catheter time of permanence < 24 h; peripheral venous cannulation time of permanence < 24 h; no postoperative homologous blood transfusion administration and hospital stay ≤ 8 d. Exclusion criteria were: The presence of other articular prosthetic replacement or bone fixation devices; chronic inflammatory diseases; chronic kidney diseases; history of recurrent infections or malignant neoplasms; previous surgery in the preceding 12 mo; diabetes mellitus; immunosuppressive drug or corticosteroid assumption. All the patients received the same antibiotic prophylaxis. All the THA were performed by the same surgical and anaesthesia team; total operative time was defined as the time taken from skin incision to completion of skin closure. At enrollment, anthropometric data, smocking status, osteoarthritis stage according to Kellgren and Lawrence, Harris Hip Score, drugs assumption and comorbidities were recorded. All the patients underwent serial blood tests, including complete blood count, presepsin (PS) and C-reactive protein 24 h before arthroplasty and at 24, 48, 72 and 96 h postoperatively and at 3, 6 and 12-mo follow-up.
RESULTS RESULTS
A total of 96 patients (51 female; 45 male; mean age = 65.74 ± 5.58) were recruited. The mean PS values were: 137.54 pg/mL at baseline, 192.08 pg/mL at 24 h post-op; 254.85 pg/mL at 48 h post-op; 259 pg/mL at 72 h post-op; 248.6 pg/mL at 96-h post-op; 140.52 pg/mL at 3-mo follow-up; 135.55 pg/mL at 6-mo follow-up and 130.11 pg/mL at 12-mo follow-up. In two patients (2.08%) a soft-tissue infection was observed; in these patients, higher levels (> 350 pg/mL) were recorded at 3-mo follow-up.
CONCLUSION CONCLUSIONS
The dosage of plasmatic PS concentration is highly recommended in patients undergoing THA before surgery to exclude the presence of an unknown infection. The PS plasmatic concentration should be also assessed at 72 h post-operatively, evaluate the maximum postoperative PS value, and at 96 h post-operatively when a decrease of presepsin should be found. The lack of a presepsin decrease at 96 h post-operatively could be a predictive factor of infection.

Identifiants

pubmed: 37485426
doi: 10.5312/wjo.v14.i7.547
pmc: PMC10359746
doi:

Types de publication

Journal Article

Langues

eng

Pagination

547-553

Informations de copyright

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Références

J Funct Morphol Kinesiol. 2022 Oct 28;7(4):
pubmed: 36412759
Anesthesiology. 2017 Apr;126(4):631-642
pubmed: 28099244
Curr Opin Infect Dis. 2017 Apr;30(2):240-247
pubmed: 28067676
Int J Immunopathol Pharmacol. 2018 Jan-Dec;31:394632017749356
pubmed: 29251000
J Infect Chemother. 2011 Dec;17(6):764-9
pubmed: 21560033
Injury. 2020 Aug;51 Suppl 3:S86-S91
pubmed: 31591005
Clin Chem Lab Med. 2015 Mar;53(4):567-73
pubmed: 24897401
Crit Care. 2013 Jul 30;17(4):R168
pubmed: 23899120
Spine (Phila Pa 1976). 2018 Apr 15;43(8):578-584
pubmed: 28816823
Am J Perinatol. 2017 May;34(6):550-556
pubmed: 27825177
Joints. 2016 Jan 31;3(4):208-14
pubmed: 26904527
Crit Care. 2013 Oct 20;17(5):R244
pubmed: 24138799
Bone Joint J. 2021 Jan;103-B(1):16-17
pubmed: 33380197
Pediatr Res. 2017 Feb;81(2):329-334
pubmed: 27925621
Crit Care. 2014 Sep 05;18(5):507
pubmed: 25190134
Ann Intensive Care. 2016 Dec;6(1):59
pubmed: 27389015
Bone Joint Res. 2022 Sep;11(9):608-618
pubmed: 36047011
J Crit Care. 2014 Dec;29(6):965-70
pubmed: 25042676
PLoS One. 2015 Jul 20;10(7):e0133057
pubmed: 26192602
J Infect Chemother. 2019 Mar;25(3):170-174
pubmed: 30473180
J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):1081-1086
pubmed: 29254318
Clin Chem Lab Med. 2013 Oct;51(10):2053-62
pubmed: 23740685
Clin Lab. 2016 Sep 1;62(9):1699-1708
pubmed: 28164588
Z Orthop Unfall. 2022 Jun;160(3):299-306
pubmed: 33296945
PLoS One. 2017 Mar 6;12(3):e0172384
pubmed: 28264059
Protein Cell. 2015 Sep;6(9):628-37
pubmed: 26135925
J Infect Chemother. 2005 Oct;11(5):234-8
pubmed: 16258819
J Clin Lab Anal. 2017 Nov;31(6):
pubmed: 28133789
Trop Med Infect Dis. 2022 Nov 07;7(11):
pubmed: 36355897
J Biol Regul Homeost Agents. 2019 Nov-Dec;34(4 Suppl. 3):259-262. Congress of the Italian Orthopaedic Research Society
pubmed: 33261287

Auteurs

Davide Bizzoca (D)

DAI Neuroscienze, Organi di Senso e Apparato Locomotore, AOU Consorziale Policlinico di Bari, Bari 70124, Italy.

Andrea Piazzolla (A)

DAI Neuroscienze, Organi di Senso e Apparato Locomotore, AOU Consorziale Policlinico di Bari, Bari 70124, Italy.

Lorenzo Moretti (L)

DAI Neuroscienze, Organi di Senso e Apparato Locomotore, AOU Consorziale Policlinico di Bari, Bari 70124, Italy.

Giovanni Vicenti (G)

Di BraiN, University of Bari "Aldo Moro", Bari 70124, Italy.

Biagio Moretti (B)

Di BraiN, University of Bari "Aldo Moro", Bari 70124, Italy.

Giuseppe Solarino (G)

Di BraiN, University of Bari "Aldo Moro", Bari 70124, Italy. giuseppe.solarino@uniba.it.

Classifications MeSH